

References - 'Prevalence of antibodies against hepatitis C virus among injecting drug users in EU Member States, 1996-2000' (Figure 9)

Belgium (French C.)

Preumont C and Bils L. *La consommation de drogues en Communauté française de Belgique: données épidémiologiques 1998*. Comité de Concertation sur l'Alcool et les autres Drogues de la Communauté Française (CCAD), Bruxelles. (unpublished data)

Belgium (Flemish C.)

De Sleutel. Jaarverslag 1999. Merelbeke, July 2000.

Denmark:

- (1) Christensen PB. *Blood-borne viral infections in Funen, a sero-epidemiologic study*. Ph.D. Thesis, University of Southern Denmark, 1999.
- (2) Københavns Commune. Survey of Drug Users in Treatment in 1998. (unpublished data)

Germany

Holbach M, Frösner G, Donnerbauer E, Dittmeier E and Holbach B. Prevalence of hepatitis A, B and C markers and risk factors for infection in patients having used intravenous drugs. [in German] *Sucht*, 1998; **44** :390-398.

Greece

- (1) Greek Organization for Combatting Drugs (OKANA). Methadone Substitution Programme - Salonica Units
- (2) National School of Public Health - Epidemiology and Biostatistics Unit, Athens

Spain

Delegación del Gobierno para Plan National Sobre Drogas (DGPNSD) *Encuesta sobre Consumidores de Heroína en Tratamiento (ECHT)*. 1996 Report. DGPNSD, Madrid, 1997.

France

- (1) Direction de la recherche, des études, de l'évaluation et des statistiques (DREES) Paris
- (2) Valenciano M, Emmanuelli J, Lert F. Unsafe injecting practices among attendees of syringe exchange programs in France. *Addiction* 2001; **96**: 597-606.

Ireland

- (1) Allwright S, Barry J, Bradley F, Long J and Thornton L. Hepatitis B, Hepatitis C and HIV in Irish Prisoners: Prevalence and Risk. The Stationery Office, Dublin, 1999.
- (2) Smyth, B., Keenan, E., O'Connor, J. (1999) Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users. *Journal of Epidemiology and Community Health*. **53**, 434-435

Italy

Ministero della Sanità - Sistema Informativo Sanitario, Dipartimento della Prevenzione, Ufficio Dipendenze Farmaci e Sostanze d'Abuso e AIDS. Rilevazione Attività nel Settore Tossicodipendenze - Anno 1999. Roma, Novembre 2000.

Luxembourg

Schlink J, Etude épidémiologique des infections HIV et à l'hépatite virale C dans les prisons luxembourgeoises, CPL, Luxembourg, 2000

Netherlands

Carsauw HHC, Rozendaal CM van, Scheepens JMFA, Hoebe CJP, Meulders WAJ, Jansen M, Dorigo-Zetsma JW and Houweling H. *Infections with HIV, HBV and HCV among injecting drug users in Heerlen/Maastricht (in the Netherlands)*. [in Dutch] Report 441100006. Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, 1997.

Austria

- (1) Inpatient Treatment Center Anton Proksch Institut Mödling (unpublished data)
- (2) Verein Wiener Sozialprojekte, low threshold facility Ganslwirt (unpublished data).

Portugal

- (1) Drug treatment Centre CAT de Xabregas – SPTT, Lisbon (unpublished data)
- (2) Drug treatment Centre CAT Boavista– SPTT, Porto (unpublished data)

Finland

National Public Health Institute (KTL) (unpublished data)

Sweden

Krook A, Albert J, Andersson S, Biberfeld G, Blomberg J, Eklund I, Engstrom A, Julander I, Kall K, Martin C, Stendahl P, Struve J and Sonnerborg A. Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology* 1997; **15**: 381-386.

UK: (England)

- (1) Judd A, Stimson GV, Hickman M, Hunter GM, Jones S, Parry JV, Madden P. Prevalence of HIV infection in a multi-site sample of injecting drug users not in contact with treatment services in England. *AIDS*. 2000; 14: 2413-5.
and
Hope VD, Judd A, Hickman M, Lamagni T, Hunter G, Stimson GV, Jones S, Donovan L, Parry JV, Gill ON. Prevalence of hepatitis C virus in current injecting drug users in England and Wales: is harm reduction working? *Am J Public Health* 2001; 91: 38-42.
- (2) Unlinked Anonymous Surveys Steering Group. Prevalence of HIV in England and Wales: 1998. Annual report of the Unlinked Anonymous Prevalence Monitoring Programme. London: Department of Health; 1999 Dec. 14 HM B4 10344 1p